drugset
drugset / Trial / NCT04236219

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

NCT04236219 ↗

Phase 1 Completed 24 enrolled Allena Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety of ALLN-346 in healthy volunteers, in this first in human, single ascending dose study. ALLN-346 is an enzyme that degrades urate in the gastrointestinal tract.

Timeline

Start
2020-09-02
Primary completion
2020-11-06
Completion
2020-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ALLN-346 Protein / enzyme biologic — Oral

Indications

No indication recorded.